

LISTING OF THE CLAIMS

We claim:

1. (Currently amended) A stent comprising a tubular basic body open at its face surfaces, the circumferential wall of which is covered at least in places with a coating system comprising first and second polymer carriers and at least ~~one~~ first, second and third pharmaceutically active ~~substance~~ substances dispersed in the first and second polymer ~~carrier~~ carriers, whereby the first, second and third pharmaceutically active ~~substance~~ substances, after implantation of the stent into a human or animal body, ~~is~~ are released into the surrounding tissue, wherein the first, second and third pharmaceutically active ~~substance~~ substances ~~exhibits~~ exhibit predetermined locally different elution characteristics in the longitudinal direction of the stent; ~~and~~
~~wherein a degradation behavior of the first polymer carrier differs from a degradation behavior of the second polymer carrier and thereby serves to differentiate the local elution characteristics wherein the first and the second pharmaceutically active substances are integrated into the first polymer carrier, wherein concentrations of the first and the second pharmaceutically active substances change over the length of the stent in a continuous manner, wherein the third pharmaceutically active substance is integrated into the second polymer carrier, and wherein the second polymer carrier exhibits a more rapid degradation behavior than the first polymer carrier, thereby releasing the third pharmaceutically active substance more rapidly and at a higher dose than the first and second pharmaceutically active substances applied to the first polymer carrier.~~
2. (Previously presented) The stent according to claim 1, wherein the first and second polymer carriers are biodegradable.

3. (Cancelled)
4. (Currently amended) The stent according to claim 1, wherein the concentration of the first pharmaceutically active substance is greater adjacent the face surfaces than in a middle portion of the stent.
- 5-14. (Cancelled)
15. (Previously presented) A stent according to claim 1, wherein a concentration of the pharmaceutically active substance is essentially the same in both the first and second polymer carriers.
16. (Currently amended) A stent comprising a tubular basic body open at its face surfaces, the circumferential wall of which is covered at least in places with a coating system comprising ~~one or more~~ a first polymer carriers and carrier incorporating a first and a second pharmaceutically active substance and a second polymer carrier incorporating a third pharmaceutically active substance, whereby the first and second pharmaceutically active substances, after implantation of the stent into a human or animal body, are released into the surrounding tissue, wherein a concentration of the first pharmaceutically active substance is greater adjacent the face surfaces than in a middle portion of the stent, and wherein a concentration of the second pharmaceutically active substance is greater in a middle portion of the stent than adjacent the face surfaces, such that with degradation of

the one or more polymer carriers, the first and second pharmaceutically active ~~substance~~
~~exhibits~~ substances exhibit predetermined locally different elution characteristics in the
longitudinal direction of the stent.

17. (Previously presented) The stent according to claim 16, wherein the one or more polymer carriers are biodegradable.
18. (New) The stent according to claim 17, wherein the second polymer carrier is localized in the middle portion of the stent.
19. (New) The stent according to claim 18, wherein the second polymer carrier exhibits a more rapid degradation behavior than the first polymer carrier, thereby releasing the third pharmaceutically active substance more rapidly and at a higher dose than the first and second pharmaceutically active substances applied to the first polymer carrier.
20. (New) The stent according to claim 17, wherein the second polymer carrier exhibits a more rapid degradation behavior than the first polymer carrier, thereby releasing the third pharmaceutically active substance more rapidly and at a higher dose than the first and second pharmaceutically active substances applied to the first polymer carrier.
21. (New) The stent according to claim 16, wherein the second polymer carrier exhibits a more rapid degradation behavior than the first polymer carrier, thereby releasing the third

pharmaceutically active substance more rapidly and at a higher dose than the first and second pharmaceutically active substances applied to the first polymer carrier.

22. (New) The stent according to claim 1, wherein the second polymer carrier is localized in a middle portion of the stent.
23. (New) The stent according to claim 2, wherein the second polymer carrier is localized in a middle portion of the stent.
24. (New) The stent according to claim 4, wherein the second polymer carrier is localized in a middle portion of the stent.